- Conditions
- Advanced Solid Tumor
- Interventions
- BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5, BNT317 DL6, BNT317 selected DLA, BNT317 selected DLB, SoC chemotherapy 1, SoC chemotherapy 2
- Biological · Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 7
- States / cities
- Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 175
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Male Factor Infertility, Female Factor Infertility
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostatic Neoplasms
- Interventions
- GM-CSF, thalidomide, docetaxel
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diarrhea, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Interventions
- Laboratory Biomarker Analysis, Micronutrient-Fortified Probiotic Yogurt, VEGF-TKI
- Other · Dietary Supplement · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Cancer
- Interventions
- docetaxel, erlotinib hydrochloride
- Drug
- Lead sponsor
- Paula Silverman, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hemophilia A
- Interventions
- BAY94-9027
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 12 Years · Male only
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 7
- States / cities
- Sacramento, California • Pensacola, Florida • Cincinnati, Ohio + 4 more
- Conditions
- End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
- Interventions
- MK-2060, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 77
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Lenvatinib, Everolimus
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Orange, California • San Diego, California + 11 more
- Conditions
- Fasting, Intermittent Fasting, Athletic Performance, Cardiovascular Risk Factor, Resting Energy Expenditure
- Interventions
- Time Restrictive Feeding, Traditional Eating Pattern
- Behavioral
- Lead sponsor
- USDA, Western Human Nutrition Research Center
- Federal
- Eligibility
- 20 Years to 40 Years · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- Hemophilia B
- Interventions
- rFIXFc
- Biological
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- Up to 17 Years · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 11
- States / cities
- Sacramento, California • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more
- Conditions
- Locally Advanced Malignant Neoplasm, Malignant Solid Tumour
- Interventions
- ALT-836 in combination with gemcitabine
- Biological
- Lead sponsor
- Altor BioScience
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Iowa City, Iowa • Rochester, New York + 1 more
- Conditions
- Kidney Cancer
- Interventions
- Contrast-enhanced Ultrasound, Perflutren lipid
- Procedure · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Infertility, Female, Reproductive Techniques, Assisted, Fertilization in Vitro
- Interventions
- Intracytoplasmic Sperm Injection (ICSI), Conventional Insemination (IVF)
- Procedure
- Lead sponsor
- Shady Grove Fertility Reproductive Science Center
- Other
- Eligibility
- Female only
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Type 2 Diabetes Mellitus, Obesity
- Interventions
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Procedure · Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- vadadustat
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 4 Months to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- Plasma exchange, Cyclophosphamide
- Procedure · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer (NSCLC)
- Interventions
- Tisotumab vedotin (HuMax-TF-ADC)
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Urothelial Carcinoma
- Interventions
- Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily + atezolizumab 1200 mg, Derazantinib 200 mg twice daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily monotherapy (QD), Derazantinib 200 mg twice daily monotherapy
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Newnan, Georgia • New York, New York • Port Jefferson Station, New York + 4 more
- Conditions
- Healthy, Chronic Kidney Disease
- Interventions
- Diet
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Infertility
- Interventions
- In-vitro fertilization using Eeva
- Device
- Lead sponsor
- Progyny, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Encino, California
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Interventions
- LY2382770, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Inglewood, California • Los Angeles, California + 25 more
- Conditions
- Detrusor Overactivity, Overactive Bladder
- Interventions
- Placebo, solifenacin
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 547 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- New York, New York • West Reading, Pennsylvania
- Conditions
- ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell
- Interventions
- Oral NKT2152
- Drug
- Lead sponsor
- NiKang Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 10 more
- Conditions
- Metastatic Renal Cell Cancer
- Interventions
- Everolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 15
- States / cities
- Springdale, Arkansas • Aurora, Colorado • Ocoee, Florida + 12 more